Neural encoding of opioid-induced analgesia
Conditions
Interventions
Group 1: NaCl, 10ml (IV), 30 minutes, blind application
Group 2: Remifentanil, 0.05 microgramm/kg/min (IV), 30 minutes, blind application
Group 3: Remifentanil, 0.05 microgramm/kg/min (IV), 30 minutes
Sponsors
Universitätsklinikum Hamburg-Eppendorf
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Healthy, fully competent, male gender, ages between 18 and 45 years, no use of illegal drugs, average alcohol consumption less than 15 glasses per week, cigarette consumption averages less than 20 cigarettes per day
Exclusion criteria
Exclusion criteria: Chronic pain conditions, acute pain in the last 4 weeks, open injuries, inflammation or skin infections, any long-term medication, participation in another drug-related study in the last 2 months, severe somatic, neurological or psychiatric illness, cancer, alcohol, medication or drug addiction, other serious health problems, current severe mental or physical exertion, hypersensitivity or intolerance to remifentanil, MRI-specific exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjects receive thermal heat stimuli during the MRI experiment, which they should assess on a scale of 0 to 100 with regard to their painfulness. Pain ratings are compared between the groups to investigate how remifentanil in combination with the blinded / open application reduces pain perception compared to NaCl. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neural activations are compared between the 3 groups, primarily in pain-processing brain regions and in the spinal cord. In addition, the activation in the descending pain system is examined, as well as the connectivity between these areas. | — |
Countries
Germany
Contacts
Public ContactAlexandra Tinnermann
Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed